In 421 analysed patients with acute ischaemic stroke given thrombolysis with or without thrombectomy, adding glenzocimab did not reduce poor outcome (mRS 4-6) at day 90 vs placebo: 21.6% vs 15.3% (OR 1.51; P=0.12). Secondary outcomes did not differ either.
RCTn = 438
Köhrmann et al. Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study